| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| S J Tsai, Y C Wang, C J Hon. Association study between cannabinoid receptor gene (CNR1) and pathogenesis and psychotic symptoms of mood disorders. American journal of medical genetics. vol 105. issue 3. 2001-12-04. PMID:11353438. |
in brain, the main active ingredient of cannabis acts via the cannabinoid cb1 receptor (cnr1) which is located on chromosome 6q14-15. |
2001-12-04 |
2023-08-12 |
Not clear |
| L Fattore, G Cossu, C M Martellotta, W Fratt. Intravenous self-administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology. vol 156. issue 4. 2001-12-04. PMID:11498718. |
delta9-tetrahydrocannabinol (delta9-thc), the main psychoactive ingredient of marijuana, as well as synthetic cannabinoid (cb1) receptor agonists, has led to negative or equivocal results when tested with the intravenous self-administration procedure, the best validated behavioural model for evaluating abuse liability of drugs in experimental animals. |
2001-12-04 |
2023-08-12 |
mouse |
| A Ménétrey, M Augsburger, C Giroud, P Mangi. [Cannabis and automobile driving]. Praxis. vol 90. issue 34. 2001-12-04. PMID:11552320. |
in forensic practice, cannabis impairment of driving performance must be related to cannabinoids blood concentrations. |
2001-12-04 |
2023-08-12 |
Not clear |
| L N Voruganti, P Slomka, P Zabel, A Mattar, A G Awa. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry research. vol 107. issue 3. 2001-12-04. PMID:11566433. |
this observation offers a plausible biological explanation for the psychotogenic effects of cannabis in vulnerable individuals, and also raises speculations about an interaction between cannabinoid and dopaminergic systems in the brain reward pathways. |
2001-12-04 |
2023-08-12 |
Not clear |
| A S Ric. Cannabinoids and pain. Current opinion in investigational drugs (London, England : 2000). vol 2. issue 3. 2001-12-04. PMID:11575713. |
recent advances have dramatically increased our understanding of cannabinoid pharmacology: the psychoactive constituents of cannabis sativa have been isolated, synthetic cannabinoids described and an endocannabinoid system identified, together with its component receptors, ligands and their biochemistry. |
2001-12-04 |
2023-08-12 |
Not clear |
| L Ferraro, M C Tomasini, T Cassano, B W Bebe, A Siniscalchi, W T O'Connor, P Magee, S Tanganelli, V Cuomo, T Antonell. Cannabinoid receptor agonist WIN 55,212-2 inhibits rat cortical dialysate gamma-aminobutyric acid levels. Journal of neuroscience research. vol 66. issue 2. 2001-12-04. PMID:11592127. |
these findings suggest that cannabinoids decrease cortical gaba levels in vivo, an action that might underlie some of the cognitive and behavioral effects of acute exposure to marijuana. |
2001-12-04 |
2023-08-12 |
rat |
| R N Kumar, W A Chambers, R G Pertwe. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. vol 56. issue 11. 2001-12-04. PMID:11703238. |
pharmacological actions and therapeutic uses of cannabis and cannabinoids. |
2001-12-04 |
2023-08-12 |
Not clear |
| T Yamaguchi, Y Hagiwara, H Tanaka, T Sugiura, K Waku, Y Shoyama, S Watanabe, T Yamamot. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice. Brain research. vol 909. issue 1-2. 2001-10-11. PMID:11478928. |
in the present study, we examined the effects of endogenous ligand 2-arachidonoylglycerol (2-ag) on naloxone-precipitated withdrawal in morphine-dependent mice, in comparison with that of two cannabinoid agonists, an ingredient of cannabis sativa delta(8)-tetrahydrocannabinol (delta(8)-thc) and the synthetic cannabinoid cb1 receptor agonist hu-210. |
2001-10-11 |
2023-08-12 |
mouse |
| E Valjent, C Pagès, M Rogard, M J Besson, R Maldonado, J Caboch. Delta 9-tetrahydrocannabinol-induced MAPK/ERK and Elk-1 activation in vivo depends on dopaminergic transmission. The European journal of neuroscience. vol 14. issue 2. 2001-10-11. PMID:11553284. |
it is now well established that central effects of delta 9-tetrahydrocannabinol (thc), the main psychoactive component of marijuana, are mediated by cb1 cannabinoid receptors. |
2001-10-11 |
2023-08-12 |
Not clear |
| T Maejima, T Ohno-Shosaku, M Kan. Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals. Neuroscience research. vol 40. issue 3. 2001-09-13. PMID:11448511. |
cannabinoid receptors are the molecular targets for the active component delta(9)-tetrahydrocannabinol of marijuana and hashish, and constitute a major family of g protein-coupled seven-transmembrane-domain receptors. |
2001-09-13 |
2023-08-12 |
Not clear |
| A H Lichtman, J L Poklis, A Poklis, D M Wilson, B R Marti. The pharmacological activity of inhalation exposure to marijuana smoke in mice. Drug and alcohol dependence. vol 63. issue 2. 2001-08-30. PMID:11376914. |
although the majority of cannabinoid users smoke marijuana, the preponderance of laboratory animal research is based on administration of delta9-tetrahydrocannabinol (delta9-thc) or other cannabinoid agents via injection. |
2001-08-30 |
2023-08-12 |
mouse |
| A H Lichtman, J L Poklis, A Poklis, D M Wilson, B R Marti. The pharmacological activity of inhalation exposure to marijuana smoke in mice. Drug and alcohol dependence. vol 63. issue 2. 2001-08-30. PMID:11376914. |
the aim of the present study was to evaluate the impact of inhaling marijuana, or ethanol-extracted placebo smoke in the mouse model of cannabinoid activity by assessing inhibition of spontaneous activity, antinociception, catalepsy, and body temperature. |
2001-08-30 |
2023-08-12 |
mouse |
| Y H Chang, S T Lee, W W Li. Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. Journal of cellular biochemistry. vol 81. issue 4. 2001-06-28. PMID:11329626. |
delta(9)-tetrahydrocannabinol (delta(9)-thc) is the major psychoactive component of marijuana and elicits pharmacological actions via cannabinoid receptors. |
2001-06-28 |
2023-08-12 |
Not clear |
| V Di Marzo, S K Goparaju, L Wang, J Liu, S Bátkai, Z Járai, F Fezza, G I Miura, R D Palmiter, T Sugiura, G Kuno. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. vol 410. issue 6830. 2001-06-07. PMID:11298451. |
however, alternative orexigenic pathways maintain food intake in mice deficient in neuropeptide y. cb1 cannabinoid receptors and the endocannabinoids anandamide and 2-arachidonoyl glycerol are present in the hypothalamus, and marijuana and anandamide stimulate food intake. |
2001-06-07 |
2023-08-12 |
mouse |
| M Guzmán, C Sánchez, I Galve-Roper. Control of the cell survival/death decision by cannabinoids. Journal of molecular medicine (Berlin, Germany). vol 78. issue 11. 2001-05-31. PMID:11269508. |
cannabinoids, the active components of cannabis sativa (marijuana), and their derivatives produce a wide spectrum of central and peripheral effects, some of which may have clinical application. |
2001-05-31 |
2023-08-12 |
Not clear |
| P D Skosnik, L Spatz-Glenn, S Par. Cannabis use is associated with schizotypy and attentional disinhibition. Schizophrenia research. vol 48. issue 1. 2001-05-31. PMID:11278156. |
these results suggest that cannabis use can mimic attentional deficits seen in acute schizophrenia and is associated with schizotypal personality, thus setting the stage for a possible cannabinoid model of sz. |
2001-05-31 |
2023-08-12 |
Not clear |
| P Robso. Therapeutic aspects of cannabis and cannabinoids. The British journal of psychiatry : the journal of mental science. vol 178. 2001-05-17. PMID:11157423. |
therapeutic aspects of cannabis and cannabinoids. |
2001-05-17 |
2023-08-12 |
Not clear |
| T Yamaguchi, Y Shoyama, S Watanabe, T Yamamot. Behavioral suppression induced by cannabinoids is due to activation of the arachidonic acid cascade in rats. Brain research. vol 889. issue 1-2. 2001-05-17. PMID:11166698. |
tetrahydrocannabinol (thc) is the principle psychoactive ingredient of marijuana and produces various psychoactive effects through the brain cannabinoid (cb1) receptor. |
2001-05-17 |
2023-08-12 |
rat |
| M J Reid, L M Bornhei. Cannabinoid-induced alterations in brain disposition of drugs of abuse. Biochemical pharmacology. vol 61. issue 11. 2001-05-10. PMID:11331071. |
because marijuana is often consumed with other drugs, the influence of cannabinoids on the brain levels of several other drugs of abuse was also determined. |
2001-05-10 |
2023-08-12 |
mouse |
| M J Reid, L M Bornhei. Cannabinoid-induced alterations in brain disposition of drugs of abuse. Biochemical pharmacology. vol 61. issue 11. 2001-05-10. PMID:11331071. |
these findings demonstrate that cannabinoids can increase the brain concentrations and pharmacological actions of several other drugs of abuse, thereby providing a biochemical basis for the common practice of using marijuana concurrently with such drugs. |
2001-05-10 |
2023-08-12 |
mouse |